ClinicalTrials.gg
CompletedNCT04969276Updated Sep 12, 2025Results posted

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

A Phase 2 interventional study of Quadrivalent Inactivated Influenza High Dose and COVID-19 mRNA Vaccine (nucleoside modified) in Influenza Immunization and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 6 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.

Enrollment
63rd of 126
306 · median 305
Started
2021
with 3 others
Phase 2
34 of 139
none open now
Registered
107th of 139
by date

Among the 139 studies in Influenza, Human by Sanofi, this one is the 63rd largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2021, is one of 34 in phase 2, and was the 107th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Influenza, Human by Sanofi, or all of them as a file.
02

Study summary

The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine administered concomitantly or singly in adults 65 years of age and older having received their second dose of the 2-dose schedule of Moderna COVID-19 vaccine at least 5 months before enrollment in the study.

Read the detailed description

Participants were in the study for 6 months (approximately 180 days).

03

Conditions studied

  • Influenza Immunization
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged greater than or equal to >= 65 years of age on the day of inclusion.
  • In good health or with underlying medical condition(s) that were judged to be stable by the Investigator. A stable medical condition was defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
  • Participants who previously received 2 injections of Moderna COVID-19 Vaccine with the second dose received at least 5 months before Visit 1.
  • Abled to attend all scheduled visits and to complied with all study procedures.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the 3 months preceding planned inclusion).
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances.
  • Previous dermal filler injection (either lips or face fillers).
  • Thrombocytopenia, IM injection.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicated IM vaccination.
  • Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with study conduct or completion.
  • Moderate or severe acute illness/infection (according to Investigator judgment) on the day of study intervention administration or febrile illness (temperature >= 100.4°Fahrenheit [F] [38.0° Celsius {C}]). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.
  • History of serious adverse reaction to any influenza or COVID-19 vaccines.
  • Personal history of Guillain-Barré syndrome (GBS).
  • Personal history of developmental delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder.
  • Known seropositivity for , , or .
  • Any condition that in the opinion of the Investigator posed a health risk to the participant if enrolled or could interfere with the evaluation of the vaccine.
  • Receipt of any vaccine in the 4 weeks preceding the study intervention(s) administration or planned receipt of any vaccine in the period between Visit 01 and 4 weeks following the study intervention(s) administration. Note: Vaccination of Group 3 participants with Fluzone High-Dose Quadrivalent vaccine at the end of the study was not considered by the Sponsor as meeting this exclusion criterion.
  • Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
  • Participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating vaccine, drug, medical device, or medical procedure.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
  • The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine

    Participants received an injection of 0.7 milliliters (mL), fluzone HD quadrivalent influenza vaccine, co-administered with 0.5 mL COVID-19 vaccine, intramuscularly (IM) on Day 1.

    Biological: Quadrivalent Inactivated Influenza High Dose · Biological: COVID-19 mRNA Vaccine (nucleoside modified)

  • Active comparator
    Group 2: Fluzone HD Quadrivalent Influenza Vaccine

    Participants received a single injection of 0.7 mL fluzone HD quadrivalent influenza vaccine, IM on Day 1.

    Biological: Quadrivalent Inactivated Influenza High Dose

  • Active comparator
    Group 3: COVID-19 Vaccine

    Participants received a single injection of 0.5 mL COVID-19 mRNA Vaccine, IM on Day 1.

    Biological: COVID-19 mRNA Vaccine (nucleoside modified)

Interventions

  • BiologicalQuadrivalent Inactivated Influenza High Dose

    Sterile suspension for injection in a pre-filled syringe Intramuscular injection

    Also known as: Fluzone HD Quadrivalent vaccine

  • Sterile suspension (white to off-white) in multidose vial Intramuscular injection

    Also known as: Moderna COVID-19 Vaccine (mRNA-1273 vaccine)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Immediate Unsolicited Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs in the CRF. Reported AEs for each arm were presented as pre-specified in the study protocol.

    Time frame: Within 30 minutes post vaccination

  2. Number of Participants With Solicited Injection Site Reactions

    A solicited reaction (SR) was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited injection site reactions included injection site pain, axillary swelling and tenderness, injection site erythema, injection site swelling, injection site induration, and injection site bruising. Reported AEs for each arm were presented as pre-specified in the study protocol.

    Time frame: Within 7 days post-vaccination

  3. Number of Participants With Solicited Systemic Reactions

    A SR was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia, shivering, fatigue, nausea and vomiting. Reported AEs for each arm were presented as pre-specified in the study protocol.

    Time frame: Within 7 days post-vaccination

  4. Number of Participants With Unsolicited Adverse Events

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.

    Time frame: Within 21 days post-vaccination

  5. Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)

    An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs was defined as one of scientific and medical concern specific to the sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was done. Reported AEs for each arm were presented as pre-specified in the study protocol.

    Time frame: From Day 1 up to 6 months post-vaccination

  6. Number of Participants With Medically Attended Adverse Events (MAAEs)

    A MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department including medical advice seeking during the study visit or routine medical care. Reported AEs for each arm were presented as pre-specified in the study protocol.

    Time frame: From Day 1 up to 6 months post-vaccination

  7. Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 1

    GMTs of anti-influenza and anti-COVID-19 antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.

    Time frame: Day 1 (pre-vaccination)

  8. Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 22

    GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.

    Time frame: Day 22 (post-vaccination)

  9. Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine and COVID-19 Vaccine Antibodies

    GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMTRs were calculated as the ratio of GMTs post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.

    Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)

  10. Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

    Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.

    Time frame: Day 1 (pre-vaccination)

  11. Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

    Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.

    Time frame: Day 22 (post-vaccination)

  12. Percentage of Participants Achieving Seroconversion Against Influenza and COVID-19 Virus Antigens

    Anti-influenza and anti-COVID-19 antibodies were measured by HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer less than (\<)10 (1/dilution) and a post-vaccination titer \>=40 (1/dilution) or a pre-vaccination titer \>=10 (1/dilution) and a \>= four-fold increase in post-vaccination titer at Day 22.

    Time frame: Day 22 (post-vaccination)

  13. Percentage of Participants With Antibody Titers >=40 (1/Dilution)

    Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.

    Time frame: Day 1 (pre-vaccination)

  14. Percentage of Participants With Antibody Titers >=40 (1/Dilution)

    Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.

    Time frame: Day 22 (post-vaccination)

  15. Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies

    GMCs of Anti-S binding IgG antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) method and were measured in binding antibody units/milliliter (BAU/mL).

    Time frame: Day 1 (pre-vaccination)

  16. Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies

    GMCs of Anti-S binding IgG antibodies were assessed using ELISA method and were measured in BAU/mL.

    Time frame: Day 22 (post-vaccination)

  17. Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies

    GMCs of Anti-S binding IgG antibodies were assessed using ELISA method. GMCR was calculated as the ratio of GMC post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.

    Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)

  18. Percentage of Participants With >=2-Fold and >=4-Fold Rise in Anti-S Binding IgG Antibodies

    Percentage of participants with \>=2-fold and \>=4-fold rise in Anti-S binding IgG antibodies at Day 22 (post-vaccination) are reported in this outcome measure. Percentage of participants with \>=2-fold rise are those for whom the computed value at Day 22 was \*2 compared to the computed value at Day 1 and percentage of participants with \>=4-fold rise are those for whom the computed value at Day 22 was \*4 compared to the computed value at Day 1.

    Time frame: Day 22 (post-vaccination)

07

Results

Posted Dec 13, 2022

Participant flow

The study was conducted at 6 sites in the United States. A total of 306 participants were enrolled between 16 July 2021 to 05 August 2021.

Participant flow — Overall Study
MilestoneGroup 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Started100101105
Safety analysis set (safas)10092104
Completed9989105
Not completed1120
Withdrew: Protocol deviation010
Withdrew: Withdrawal by subject1100
Withdrew: Lost to follow-up010

Outcome measures

PrimaryNumber of Participants With Immediate Unsolicited Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs in the CRF. Reported AEs for each arm were presented as pre-specified in the study protocol.

Time frame:
Within 30 minutes post vaccination
Reported as:
Count of participants · Participants
Number of Participants With Immediate Unsolicited Adverse Events (AEs)
ParticipantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Number of Participants With Immediate Unsolicited Adverse Events (AEs)110
PrimaryNumber of Participants With Solicited Injection Site Reactions

A solicited reaction (SR) was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited injection site reactions included injection site pain, axillary swelling and tenderness, injection site erythema, injection site swelling, injection site induration, and injection site bruising. Reported AEs for each arm were presented as pre-specified in the study protocol.

Time frame:
Within 7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions
ParticipantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Injection site pain825492
Axillary swelling221
Axillary tenderness333
Injection site erythema221032
Injection site swelling15627
Injection site induration12322
Injection site bruising704
PrimaryNumber of Participants With Solicited Systemic Reactions

A SR was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia, shivering, fatigue, nausea and vomiting. Reported AEs for each arm were presented as pre-specified in the study protocol.

Time frame:
Within 7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Reactions
ParticipantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Fever12112
Headache521855
Malaise461359
Myalgia502064
Arthralgia24827
Shivering32622
Fatigue622673
Nausea32527
Vomiting431
PrimaryNumber of Participants With Unsolicited Adverse Events

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.

Time frame:
Within 21 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events
ParticipantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Number of Participants With Unsolicited Adverse Events171115
PrimaryNumber of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)

An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs was defined as one of scientific and medical concern specific to the sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was done. Reported AEs for each arm were presented as pre-specified in the study protocol.

Time frame:
From Day 1 up to 6 months post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)
ParticipantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
SAEs203
AESIs101
PrimaryNumber of Participants With Medically Attended Adverse Events (MAAEs)

A MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department including medical advice seeking during the study visit or routine medical care. Reported AEs for each arm were presented as pre-specified in the study protocol.

Time frame:
From Day 1 up to 6 months post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended Adverse Events (MAAEs)
ParticipantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Number of Participants With Medically Attended Adverse Events (MAAEs)10617
PrimaryGeometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 1

GMTs of anti-influenza and anti-COVID-19 antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.

Time frame:
Day 1 (pre-vaccination)
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 1
titersGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N1: Pre-vaccination55.8 (44.2 to 70.4)45.5 (34.7 to 59.7)49.7 (37.7 to 65.4)
A/H3N2: Pre-vaccination95.0 (77.5 to 116)85.4 (66.3 to 110)80.3 (63.1 to 102)
B/Yamagata: Pre-vaccination221 (178 to 274)204 (159 to 262)203 (163 to 252)
B/Victoria: Pre-vaccination163 (137 to 194)155 (127 to 190)165 (136 to 201)
PrimaryGeometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 22

GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.

Time frame:
Day 22 (post-vaccination)
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 22
titersGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N1: Post-vaccination363 (276 to 476)366 (272 to 491)41.2 (31.4 to 54.2)
A/H3N2: Post-vaccination286 (233 to 352)315 (257 to 386)76.5 (61.1 to 95.8)
B/Yamagata: Post-vaccination429 (350 to 525)471 (378 to 588)198 (160 to 243)
B/Victoria: Post-vaccination377 (325 to 438)390 (327 to 465)176 (146 to 212)
PrimaryGeometric Mean Titers Ratio (GMTR) of Influenza Vaccine and COVID-19 Vaccine Antibodies

GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMTRs were calculated as the ratio of GMTs post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.

Time frame:
Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Reported as:
Geometric mean · ratio
Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine and COVID-19 Vaccine Antibodies
ratioGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N16.35 (4.88 to 8.26)8.10 (6.09 to 10.8)0.868 (0.821 to 0.917)
A/H3N23.06 (2.54 to 3.70)3.54 (2.82 to 4.45)0.940 (0.870 to 1.01)
B/Yamagata1.94 (1.68 to 2.23)2.27 (1.84 to 2.79)0.983 (0.918 to 1.05)
B/Victoria2.27 (1.96 to 2.63)2.44 (2.01 to 2.96)1.05 (0.972 to 1.14)
PrimaryPercentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.

Time frame:
Day 1 (pre-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)
percentage of participantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N1: Pre-vaccination97.0 (91.4 to 99.4)94.5 (87.6 to 98.2)91.1 (83.8 to 95.8)
A/H3N2: Pre-vaccination100 (96.3 to 100)98.9 (94.0 to 100)99.0 (94.6 to 100)
B/Yamagata: Pre-vaccination100 (96.3 to 100)100 (96.0 to 100)99.0 (94.6 to 100)
B/Victoria: Pre-vaccination100 (96.3 to 100)100 (96.0 to 100)100 (96.4 to 100)
PrimaryPercentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)

Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.

Time frame:
Day 22 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)
percentage of participantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N1: Post-vaccination100 (96.3 to 100)100 (95.8 to 100)91.2 (83.9 to 95.9)
A/H3N2: Post-vaccination100 (96.3 to 100)100 (95.8 to 100)99.0 (94.7 to 100)
B/Yamagata: Post-vaccination100 (96.3 to 100)100 (95.8 to 100)99.0 (94.7 to 100)
B/Victoria: Post-vaccination100 (96.3 to 100)100 (95.8 to 100)100 (96.4 to 100)
PrimaryPercentage of Participants Achieving Seroconversion Against Influenza and COVID-19 Virus Antigens

Anti-influenza and anti-COVID-19 antibodies were measured by HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer less than (\<)10 (1/dilution) and a post-vaccination titer \>=40 (1/dilution) or a pre-vaccination titer \>=10 (1/dilution) and a \>= four-fold increase in post-vaccination titer at Day 22.

Time frame:
Day 22 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Seroconversion Against Influenza and COVID-19 Virus Antigens
percentage of participantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N168.8 (58.5 to 77.8)72.1 (61.4 to 81.2)0.0 (0.0 to 3.6)
A/H3N243.8 (33.6 to 54.3)47.7 (36.8 to 58.7)0.0 (0.0 to 3.6)
B/Yamagata17.7 (10.7 to 26.8)20.9 (12.9 to 31.0)1.0 (0.0 to 5.4)
B/Victoria30.2 (21.3 to 40.4)24.4 (15.8 to 34.9)1.0 (0.0 to 5.4)
PrimaryPercentage of Participants With Antibody Titers >=40 (1/Dilution)

Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.

Time frame:
Day 1 (pre-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With Antibody Titers >=40 (1/Dilution)
percentage of participantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N1: Pre-vaccination65.7 (55.4 to 74.9)56.0 (45.2 to 66.4)59.4 (49.2 to 69.1)
A/H3N2: Pre-vaccination83.8 (75.1 to 90.5)79.1 (69.3 to 86.9)77.2 (67.8 to 85.0)
B/Yamagata: Pre-vaccination97.0 (91.4 to 99.4)90.1 (82.1 to 95.4)96.0 (90.2 to 98.9)
B/Victoria: Pre-vaccination99.0 (94.5 to 100)94.5 (87.6 to 98.2)95.0 (88.8 to 98.4)
PrimaryPercentage of Participants With Antibody Titers >=40 (1/Dilution)

Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.

Time frame:
Day 22 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With Antibody Titers >=40 (1/Dilution)
percentage of participantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
A/H1N1: Post-vaccination94.8 (88.4 to 98.3)95.3 (88.5 to 98.7)53.9 (43.8 to 63.8)
A/H3N2: Post-vaccination96.9 (91.2 to 99.4)100 (95.8 to 100)72.5 (62.8 to 80.9)
B/Yamagata: Post-vaccination100 (96.3 to 100)98.8 (93.7 to 100)96.1 (90.3 to 98.9)
B/Victoria: Post-vaccination100 (96.3 to 100)100 (95.8 to 100)96.1 (90.3 to 98.9)
PrimaryGeometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies

GMCs of Anti-S binding IgG antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) method and were measured in binding antibody units/milliliter (BAU/mL).

Time frame:
Day 1 (pre-vaccination)
Reported as:
Geometric mean · BAU/mL
Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies
BAU/mLGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies565 (479 to 666)462 (382 to 560)552 (461 to 662)
PrimaryGeometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies

GMCs of Anti-S binding IgG antibodies were assessed using ELISA method and were measured in BAU/mL.

Time frame:
Day 22 (post-vaccination)
Reported as:
Geometric mean · BAU/mL
Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies
BAU/mLGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies7634 (6445 to 9042)395 (311 to 502)7904 (6883 to 9077)
PrimaryGeometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies

GMCs of Anti-S binding IgG antibodies were assessed using ELISA method. GMCR was calculated as the ratio of GMC post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.

Time frame:
Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Reported as:
Geometric mean · ratio
Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies
ratioGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies13.7 (11.2 to 16.8)0.875 (0.745 to 1.03)14.2 (12.0 to 16.9)
PrimaryPercentage of Participants With >=2-Fold and >=4-Fold Rise in Anti-S Binding IgG Antibodies

Percentage of participants with \>=2-fold and \>=4-fold rise in Anti-S binding IgG antibodies at Day 22 (post-vaccination) are reported in this outcome measure. Percentage of participants with \>=2-fold rise are those for whom the computed value at Day 22 was \*2 compared to the computed value at Day 1 and percentage of participants with \>=4-fold rise are those for whom the computed value at Day 22 was \*4 compared to the computed value at Day 1.

Time frame:
Day 22 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With >=2-Fold and >=4-Fold Rise in Anti-S Binding IgG Antibodies
percentage of participantsGroup 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
>= 2-fold rise97.9 (92.7 to 99.7)3.5 (0.7 to 9.9)98.0 (93.1 to 99.8)
>= 4-fold rise92.7 (85.6 to 97.0)2.3 (0.3 to 8.1)95.1 (88.9 to 98.4)

Adverse events

Collected over Unsolicited AEs were collected from Day 1 up to 21 days post-vaccination. SR data were collected up to 7 days post-vaccination. SAE data were collected from Day 1 up to 6 months post-vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine0/100 (0%)2/100 (2%)94/100 (94%)
Group 2: Fluzone HD Quadrivalent Influenza Vaccine0/92 (0%)0/92 (0%)65/92 (70.7%)
Group 3: COVID-19 Vaccine0/104 (0%)3/104 (2.9%)100/104 (96.2%)
Most frequent serious events
Most frequent serious events
EventGroup 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Myocardial InfarctionCardiac disorders1/1000/920/104
Papillary Thyroid CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1000/920/104
Thyroid MassEndocrine disorders0/1000/921/104
Diabetic GastroparesisGastrointestinal disorders0/1000/921/104
Pelvic FractureInjury, poisoning and procedural complications0/1000/921/104
ExostosisMusculoskeletal and connective tissue disorders0/1000/921/104
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGroup 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 Vaccine
Injection Site PainGeneral disorders82/10054/9292/104
FatigueGeneral disorders62/10026/9273/104
MyalgiaMusculoskeletal and connective tissue disorders50/10020/9264/104
MalaiseGeneral disorders46/10013/9259/104
HeadacheNervous system disorders52/10018/9255/104
NauseaGastrointestinal disorders32/1006/9227/104
ChillsGeneral disorders32/1006/9222/104
Injection Site ErythemaGeneral disorders22/10010/9232/104
Injection Site SwellingGeneral disorders15/1006/9227/104
ArthralgiaMusculoskeletal and connective tissue disorders24/1008/9227/104

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(years)Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 VaccineTotal
Mean71.3 ± 4.7671.7 ± 5.1672.0 ± 4.8971.7 ± 4.93
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 VaccineTotal
Female555463172
Male454742134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 VaccineGroup 2: Fluzone HD Quadrivalent Influenza VaccineGroup 3: COVID-19 VaccineTotal
American Indian or Alaska Native0000
Asian2002
Native Hawaiian or Other Pacific Islander0123
Black or African American1405
White9495103292
More than one race1102
Unknown or Not Reported2002
08

Study locations

6 sites
  • Investigational Site Number :8400003
    Glendale, Arizona 85306, United States
  • Investigational Site Number :8400006
    San Diego, California 92108, United States
  • Investigational Site Number :8400004
    Vista, California 92083, United States
  • Investigational Site Number :8400005
    Centennial, Colorado 80112, United States
  • Investigational Site Number :8400001
    Peoria, Illinois 61614, United States
  • Investigational Site Number :8400002
    Austin, Texas 78705, United States
09

References and documents

Publications

  • Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, Pandey A, Perez L, Sater N, Shrestha A, Wague S, Samson SI. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged >/=65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022 Apr;10(4):392-402. doi: 10.1016/S2213-2600(21)00557-9. Epub 2022 Feb 1. PubMed 35114141 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2022, 6 months.

Results were first posted in Dec 2022, 10 months after primary completion.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 6 months is below that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2021
First posted
Jul 20, 2021
StartActual
Jul 16, 2021
Primary completionActual
Feb 8, 2022
CompletionActual
Feb 8, 2022
Results first posted
Dec 13, 2022
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04969276
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Jul 16, 2021
Primary completion
Feb 8, 2022
Completion
Feb 8, 2022
Results posted
Dec 13, 2022
Last update
Sep 12, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion